Juniper Pharma Services' co-founder awarded CBE in the Queen's New Year's Honours List
BOSTON, Dec. 29, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP), a diversified healthcare company focused on women's health, today announced that Juniper Pharma Services co-founder Martyn Davies, PhD, has been appointed as a Commander of the Order of the British Empire (CBE) in Her Majesty's 2018 New Year's Honours List. The honors system recognizes people who have made achievements in public life and have committed themselves to serving and helping Britain. Honorees are proposed by a committee and then approved by the Prime Minister and the Queen. Dr. Davies will officially receive his CBE medal at an Investiture in 2018.
Dr. Davies has been granted one of the United Kingdom's most prestigious awards in recognition of his contribution to science and his ground-breaking achievements in pharmaceutical research and drug development.
"This is such a wonderful honor. Martyn has done so much to advance pharmaceutical science across the world and is a wonderful human being as well," said Robert Langer, David H. Koch Institute Professor at Massachusetts Institute of Technology.
Alicia Secor, President and Chief Executive Officer at Juniper Pharmaceuticals, said: "We are extremely proud of Martyn as he receives this incredible honor. It is richly deserved given his consistently excellent academic and commercial contribution to drug research and pharmaceutical product development and the remarkable contribution he has made to the industry."
Now an advisor to the board of Juniper Pharmaceuticals and Chair of Juniper's Scientific Advisory Board, Dr. Davies is also an Emeritus Professor at the School of Pharmacy within The University of Nottingham. Dr. Davies co-founded Molecular Profiles (now Juniper Pharma Services) in 1997 and has played a significant role in the contract development and manufacturing organization's rapid growth and expansion over the last 20 years having worked on several hundred products, including over half of the world's top 20 blockbuster drugs. In 2013, the company was acquired by Columbia Laboratories (now Juniper Pharmaceuticals). Dr. Davies originally qualified as a pharmacist, with first-class honors before earning his PhD from the Chelsea School of Pharmacy (now King's College) in 1984. He joined the University of Nottingham in 1985 and went on to become Head of School from 2000 to 2003.
During his academic career, Dr. Davies has published 425 scientific papers and supervised over 70 PhD students and mentored over 40 postdoctoral fellows. He is a Fellow of the Controlled Release Society, UK Association of Pharmaceutical Scientists, Royal Society of Chemistry, American Institute of Biological Engineering and Royal Pharmaceutical Society of Great Britain and sits on the editorial boards of many journals including the Journal of Controlled Release, Journal of Pharmaceutical Sciences and European Journal of Pharmaceutical Sciences.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. The Company is also leveraging its differentiated intravaginal ring technology, which offers the potential to address unmet needs in women's health. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.
About Juniper Pharma Services
Juniper Pharma Services Ltd., a wholly owned subsidiary of Juniper Pharmaceuticals, Inc., is a contract development and manufacturing organisation (CDMO) that specialises in small molecule development. Its development services extend from pre-formulation and formulation development to clinical trial manufacturing, with specialist capabilities on working with or around the properties of challenging drug molecules. Juniper Pharma Services is also renowned for its expertise and toolkit to analytically resolve some of the toughest issues during development and relating to intellectual property issues. The company's services are dedicated to pharmaceutical, biopharmaceutical and healthcare companies across the globe. For more information, please visit www.juniperpharma.com
For further information, images and interview opportunities with Juniper Pharma Services, please contact Matthew Dent at ramarketing | [email protected] | +44 (0)7746 275 098 |
Investor Contact:
Argot Partners
Laura Perry or Heather Savelle
212-600-1902
[email protected]
[email protected]
SOURCE Juniper Pharmaceuticals, Inc.
Share this article